MiNK Therapeutics, Inc. (INKT) Tops Q2 EPS by 5c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q2 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Bureau Veritas agrees to sell oil and coal testing unit for €470M
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations